Abstract
ST-246, a potent orthopoxvirus egress inhibitor, is safe and effective at preventing disease and death in studies of small-animal models involving challenge by several different pathogenic poxviruses. In this report, the antiviral efficacy of ST-246 in treatment of nonhuman primates infected with variola virus or monkeypox virus was assessed. The data indicate that oral dosing once per day with ST-246 protects animals from poxvirus disease, as measured by reductions in viral load and numbers of lesions and enhancement of survival. Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Cite
CITATION STYLE
Huggins, J., Goff, A., Hensley, L., Mucker, E., Shamblin, J., Wlazlowski, C., … Hruby, D. (2009). Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrobial Agents and Chemotherapy, 53(6), 2620–2625. https://doi.org/10.1128/AAC.00021-09
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.